Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has collected capital from investors including TUS-Holdings.

Robocath, a France-based developer of a cardiovascular disease treatment system developer, raised €40m ($43.4m) in a series C round yesterday backed by Luxembourg CLIIF, an investment fund managed by the Tsinghua University-affiliated TUS-Holdings,
Medical device manufacturer MicroPort Scientific led the round, which also included regional investment vehicles Go Capital, NCI and Normandie Participations, and national investment funds M Capital and Supernova Invest.
Financial services firm Crédit Agricole’s Unexo and Crédit Agricole Normandie units filled out the round with investment firms CS Group and Anaxago, private equity fund Zhejiang Silk Road Fund, an entity called Cardio Participations and Caisse d’Epargne Normandie, a division of cooperative bank Caisse d’Epargne.
Robocath is working on robotic-assisted medical devices for cardiovascular diseases. Its inaugural product, R-One, is designed to improve the safety of coronary angioplasty, a procedure that involves placing stents into the arteries that supply the heart with blood.
The…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in